When looking at our recent coverage on Femtech Insider one could argue that the women’s health industry is experiencing a bit of a transformation these days with the integration of GLP-1 agonists into various health platforms and services.
Originally developed for diabetes management, the drugs have recently since gained prominence for their efficacy in weight loss, with potential benefits also extending to cardiovascular health, fertility and beyond.
As companies across the femtech spectrum—from sexual wellness brands to menopause-focused platforms—incorporate GLP-1s into their offerings, I think it’s crucial to have a closer look at the implications, challenges, and also the potential consequences of this trend.
But let’s start from the beginning…
The Rise of GLP-1s: From Diabetes Treatment to Weight Loss Phenomenon
The GLP-1 story actually began in the diabetes treatment space. Drugs like semaglutide (aka Ozempic) were initially approved for managing Type 2 diabetes. However, a significant side effect—weight loss—caught the attention of both patients and healthcare providers. This led to the development and approval of higher-dose versions specifically for weight management, such as Wegovy (semaglutide) and Saxenda (liraglutide).
You’ve found some of our exclusive Inner Circle Content.
This article is only available for our Inner Circle Members. To read on:
Kathrin Folkendt is the Founder & CEO of Femtech Insider, the globally leading publication on all things femtech. She usually writes about women's health innovation, health equity, and entrepreneurship.
